Anti-SPART/ SPG20/ TAHCCP1 monoclonal antibody

Anti-SPART/ SPG20/ TAHCCP1 antibody for FACS & in-vivo assay

Target products collectionGo to SPART/SPART products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP2335-Ab-1/ GM-Tg-hg-MP2335-Ab-2Anti-Human SPART monoclonal antibodyHuman
GM-Tg-rg-MP2335-Ab-1/ GM-Tg-rg-MP2335-Ab-2Anti-Rat SPART monoclonal antibodyRat
GM-Tg-mg-MP2335-Ab-1/ GM-Tg-mg-MP2335-Ab-2Anti-Mouse SPART monoclonal antibodyMouse
GM-Tg-cynog-MP2335-Ab-1/ GM-Tg-cynog-MP2335-Ab-2Anti-Cynomolgus/ Rhesus macaque SPART monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP2335-Ab-1/ GM-Tg-felg-MP2335-Ab-2Anti-Feline SPART monoclonal antibodyFeline
GM-Tg-cang-MP2335-Ab-1/ GM-Tg-cang-MP2335-Ab-2Anti-Canine SPART monoclonal antibodyCanine
GM-Tg-bovg-MP2335-Ab-1/ GM-Tg-bovg-MP2335-Ab-2Anti-Bovine SPART monoclonal antibodyBovine
GM-Tg-equg-MP2335-Ab-1/ GM-Tg-equg-MP2335-Ab-2Anti-Equine SPART monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP2335-Ab-1/ GM-Tg-hg-MP2335-Ab-2; GM-Tg-rg-MP2335-Ab-1/ GM-Tg-rg-MP2335-Ab-2;
GM-Tg-mg-MP2335-Ab-1/ GM-Tg-mg-MP2335-Ab-2; GM-Tg-cynog-MP2335-Ab-1/ GM-Tg-cynog-MP2335-Ab-2;
GM-Tg-felg-MP2335-Ab-1/ GM-Tg-felg-MP2335-Ab-2; GM-Tg-cang-MP2335-Ab-1/ GM-Tg-cang-MP2335-Ab-2;
GM-Tg-bovg-MP2335-Ab-1/ GM-Tg-bovg-MP2335-Ab-2; GM-Tg-equg-MP2335-Ab-1/ GM-Tg-equg-MP2335-Ab-2
Products NameAnti-SPART monoclonal antibody
Formatmab
Target NameSPART
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-SPART benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species SPART/ SPG20/ TAHCCP1 VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP2335
    Target NameSPART
    Gene ID23111,229285,295053,693663,477303,101085013,534027,100062426
    Gene Symbol and SynonymsmKIAA0610,SPART,SPG20,TAHCCP1
    Uniprot AccessionQ8N0X7,A0JNJ3
    Uniprot Entry NameSPART_HUMAN,SPART_BOVIN
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000133104
    Target ClassificationN/A

    The target: SPART, gene name: SPART, also named as SPG20, TAHCCP1. This gene encodes a protein containing a MIT (Microtubule Interacting and Trafficking molecule) domain, and is implicated in regulating endosomal trafficking and mitochondria function. The protein localizes to mitochondria and partially co-localizes with microtubules. Stimulation with epidermal growth factor (EGF) results in protein translocation to the plasma membrane, and the protein functions in the degradation and intracellular trafficking of EGF receptor. Multiple alternatively spliced variants, encoding the same protein, have been identified. Mutations associated with this gene cause autosomal recessive spastic paraplegia 20 (Troyer syndrome). [provided by RefSeq, Nov 2008].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.